ArticleDrug delivery and translational research2026
Magnetically controlled delivery capsule endoscopy for precise drug delivery to intestinal lesions.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Current drug delivery devices can't deliver drugs toward targeted intestinal lesions non-invasively. A novel magnetically controlled delivery capsule endoscopy (MDCE) system was developed to accurately deliver topical therapy toward intestinal lesions under real-time optical visualization. We aimed to evaluate the feasibility and efficacy of this MDCE system in precisely targeted delivery of topical therapy. The delivery feasibility of the MDCE were first evaluated using an ex vivo swine intestinal model. In this model, simulated lesions (n = 27) were created and marked with a pre-selected dye (0.1% methylene blue). The MDCE delivery processes for small intestine lesions were conducted in four Bama miniature pigs. The feasibility of MDCE was defined as successful drug delivery to specific simulated small bowel lesion under optical surveillance. Efficacy was evaluated using parameters including image quality, maneuverability of the MDCE, and the time required for aiming and drug delivery taken by MDCE. The MDCE system demonstrated robust feasibility in an ex vivo intestinal model, achieving over 80% targeting success rate across 27 lesions at various orientations. This precision was successfully translated in vivo, with 91.7% (22/24) of target lesions precisely stained. Except for two raised lesions, 22 of them were precisely stained. The image quality and the maneuverability of the MDCE system were both graded as the best. Further analysis of procedural efficiency revealed that while the time for aiming lesions (16 s to 191 s) was longer in the small intestine than in the colon, especially when aiming at flat lesions (p = 0.0304), the rapid dye delivery time (4 s to 11 s) remained consistent across all locations and lesion types (p > 0.05). This study confirmed the feasibility and efficacy of the MDCE system for delivering targeted drug to specific intestinal lesions with real-time, vision-based monitoring in swine models.
Indexed as
Identifiers
41649738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.